Cryosite (ASX:CTE) Beginning Cash Position: A$5.06 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CTE Cryosite Ltd ASX:CTE
49 GF Score
Price A$1.30
GF Value A$0.95
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Beginning Cash Position?

Cryosite ASX:CTE 49 Beginning Cash Position is A$5.06 Mil as of Dec. 2025. GuruFocus rates ASX:CTE with a GF Score™ of 49/100 and a GF Value™ of A$0.95 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Cryosite's Beginning Cash Position for the quarter that ended in Dec. 2025 was A$5.06 Mil.

Cryosite's quarterly Beginning Cash Position declined from Dec. 2024 (A$4.70 Mil) to Jun. 2025 (A$4.49 Mil) but then increased from Jun. 2025 (A$4.49 Mil) to Dec. 2025 (A$5.06 Mil).

Cryosite's annual Beginning Cash Position declined from Jun. 2023 (A$5.34 Mil) to Jun. 2024 (A$4.73 Mil) and declined from Jun. 2024 (A$4.73 Mil) to Jun. 2025 (A$4.70 Mil).

Cryosite Beginning Cash Position Related Terms

Cryosite Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Cryosite's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Beginning Cash Position Chart

Cryosite Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.06 3.88 5.34 4.73 4.70

Cryosite Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.73 5.93 4.70 4.49 5.06
ASX:CTE
49GF Score
Cryosite Ltd ASX:CTE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$5.06 Mil mean?
Cryosite (ASX:CTE) has a Beginning Cash Position of A$5.06 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cryosite and its competitors.
Is Cryosite's Beginning Cash Position too high?
Cryosite's current Beginning Cash Position is A$5.06 Mil. Overall, Cryosite has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Beginning Cash Position compare to TMO and DHR?
Cryosite's Beginning Cash Position of A$5.06 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cryosite and its competitors. Cryosite's current Beginning Cash Position is A$5.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.95, compared to a current price of A$1.30 — trading 36.8% above its estimated fair value. The current Beginning Cash Position is A$5.06 Mil. Cryosite's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Beginning Cash Position is A$5.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.30 is trading 36.8% above its estimated GF Value™ of A$0.95. GuruFocus considers Cryosite to be Significantly Overvalued.

Key valuation signals for ASX:CTE:

  • Beginning Cash Position: A$5.06 Mil
  • GF Value™: A$0.95 vs. price of A$1.30 (36.8% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
49GF Score

Get the complete analysis for ASX:CTE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.30
Price
A$0.95
GF Value